Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jun 17, 2011 (rev. 1)

Premium

Accelrys has disclosed in a filing with the US Securities and Exchange Commission that Steven Goldby, a member of the company’s board of directors, will not stand for re-election at the end of his current term.

Goldby notified Accelrys of his decision last month. The company said his decision was based on personal reasons and did not involve any disagreement with the Accelrys operations, policies or practices. He will continue to perform his duties until his term expires later this year.


David Hardison and Gregg Capone have joined Recombinant’s senior management team.

Hardison takes on the role of managing director of health sciences at Recombinant, focusing on strategic consulting and business development for life science companies and healthcare providers.

Prior to joining the firm, he served as vice president and chief health scientist at Science Applications International Corporation. He has also served as chairman of the board of CDISC and held leadership positions at First Consulting Group, Carolina Medicorp (now Novant Health), Wheaton Franciscan Services, Quorum Health Resources, and Hospital Corporation of America.

Capone will serve as Recombinant’s managing director of services and will oversee the company’s delivery teams.

Most recently, Capone worked as the senior director of account management at NaviNet and has held senior roles at Edgewater Technology.


GenomeQuest has tapped Gerry Higgins to serve as its first healthcare innovation officer.

In his new role, Higgins will work with partner to applying the company's proprietary technology to the development of whole-genome and multi-gene diagnostics. As part of his duties, he will work closely with clinicians at hospitals and academic research centers, and partner with commercial laboratories and pharmaceutical companies.

Prior to taking on the position at GenomeQuest, Higgins worked as vice president for Hoffmann-La Roche Pharmaceuticals and as the director of clinical informatics and chief innovation officer for MedStar Health.

He also founded and raised financing for SimQuest, a company that focused on biomedical informatics, medical modeling, and simulation; and served as US vice president of research and development at Laerdal Medical.


The Luxembourg Centre for Systems Biomedicine has selected Reinhard Schneider to set up and lead its central bioinformatics core.

Schneider joins the center from the European Molecular Biology Laboratory. In his new role, he will focus on creating infrastructure to merge data from laboratory experiments with models from computer-based biological research. In addition, his team will design techniques and programs for improved data analysis.


David Haussler, professor of biomolecular engineering in the Baskin School of Engineering at University of California, Santa Cruz, has been chosen to receive the 2011 Weldon Memorial Prize given by the University of Oxford.

The prize is awarded for contributions to the development of mathematical or statistical methods applied to problems in biology.

Haussler is the founder of the Genome 10K project, which aims to assemble the genome sequences of 10,000 vertebrate species. He is also involved in data analysis for the Cancer Genome Atlas and has developed a cancer genomics browser that’s designed to help researchers find patterns in large sets of clinical and genomic data from cancer studies.

He joined UCSC’s faculty in 1986 and currently serves as the director of the California Institute for Quantitative Biosciences.


The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.